Cangrelor Use Patterns and Transition to Oral P2Y₁₂ Inhibitors Among Patients With Myocardial Infarction: Initial...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Cangrelor reduces percutaneous coronary intervention-related ischemic complications without increasing major bleeding in clinical trials.
• Routine clinical practice use and transition protocols for cangrelor require examination.

Purpose of the Study:

• To examine cangrelor use and transition to oral P2Y12 inhibitors in routine clinical practice.
• To identify interhospital variability in cangrelor administration and care transitions.

Main Methods:

• The CAMEO registry, a multicenter, retrospective observational study, collected data on myocardial infarction patients undergoing percutaneous coronary intervention.
• Phase 1 analyzed cangrelor use across hospitals (n=482); Phase 2 compared cangrelor-treated (n=873) vs. non-cangrelor-treated patients (2:1 ratio).

Main Results:

• Cangrelor use varied widely (6.0%-100%) across hospitals.
• Most patients transitioned to ticagrelor, but 16.4% had >1-hour gaps before oral P2Y12 inhibitor initiation.
• Only 27.3% of patients received cangrelor dosing and transition consistent with pivotal trials and FDA label.

Conclusions:

• Significant interhospital variability exists in cangrelor administration and transition to oral P2Y12 inhibitors.
• Findings indicate opportunities to optimize cangrelor dosing, infusion duration, and care transitions from catheterization lab to ward.